Enfortumab vedotin for treating locally advanced or metastatic urothelial cancer after 2 therapies [ID3845]
Proposed [GID-TA10727] Expected publication date: TBC
Search results
1780 results
-
-
LN-145 for treating recurrent, persistent or metastatic cervical cancer [ID3844]
Proposed [GID-TA10728] Expected publication date: TBC
-
177Lu-PSMA-617 for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more therapies [ID3840]
Proposed [GID-TA10730] Expected publication date: TBC
-
Aducanumab for treating mild cognitive impairment in early Alzheimer's disease [ID3763]
Proposed [GID-TA10739] Expected publication date: TBC
-
Eflornithine with sulindac for treating familial adenomatous polyposis [ID1543]
Proposed [GID-TA10536] Expected publication date: TBC
-
Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after 1 systemic treatment [ID3869]
Proposed [GID-TA10757] Expected publication date: TBC
-
Lurbinectedin with doxorubicin for treating advanced small-cell lung cancer after platinum-based chemotherapy [ID3872]
Proposed [GID-TA10758] Expected publication date: TBC
-
Netarsudil-latanoprost for previously treated open-angle glaucoma or ocular hypertension [ID1363]
Proposed [GID-TA10741] Expected publication date: TBC
-
Dapagliflozin for treating chronic kidney disease [ID3866]
Proposed [GID-TA10808] Expected publication date: TBC
-
Avatrombopag in combination for treating chronic immune thrombocytopenia [ID3838]
Proposed [GID-TA10738] Expected publication date: TBC
-
Burosumab for treating X-linked hypophosphataemia in adults [ID3822]
Proposed [GID-TA10733] Expected publication date: TBC
-
Perampanel for adjunctive treatment of partial onset or generalised tonic-clonic seizures in children aged below 12 years with epilepsy ID1587
Proposed [GID-TA10519] Expected publication date: TBC
-
Atezolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (CDF Review of TA492) ID3777
Proposed [GID-TA10810] Expected publication date: 22 October 2021
-
Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID3860]
Proposed [GID-TA10746] Expected publication date: TBC
-
Tofacitinib for treating active ankylosing spondylitis [ID3865]
Proposed [GID-TA10771] Expected publication date: TBC
-
Lenvatinib with pembrolizumab for untreated advanced or unresectable hepatocellular carcinoma [ID3930]
Proposed [GID-TA10811] Expected publication date: TBC
-
Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer [ID3896]
Proposed [GID-TA10812] Expected publication date: TBC
-
Trastuzumab deruxtecan for treating HER2-negative metastatic or unresectable breast cancer after chemotherapy [ID3935]
Proposed [GID-TA10813] Expected publication date: TBC
-
Trastuzumab deruxtecan for treating HER2-mutated unresectable or metastatic non-squamous non-small-cell lung cancer after 1 or more therapies [ID3934]
Proposed [GID-TA10814] Expected publication date: TBC
-
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after 2 or more therapies [ID3933]
Proposed [GID-TA10815] Expected publication date: TBC
-
Mosunetuzumab for treating relapsed or refractory B-cell non-Hodgkin lymphoma [ID3931]
Proposed [GID-TA10816] Expected publication date: TBC
-
Belzutifan for treating clear-cell renal carcinoma caused by von Hippel-Lindau disease [ID3932]
Proposed [GID-TA10817] Expected publication date: TBC
-
Avatrombopag for treating chemotherapy-induced thrombocytopenia in non-haematological cancers [ID3837]
Proposed [GID-TA10737] Expected publication date: TBC
-
Empagliflozin for treating chronic heart failure with reduced ejection fraction [ID3826]
Proposed [GID-TA10719] Expected publication date: TBC
-
Tofacitinib for treating juvenile idiopathic arthritis [ID2718]
Proposed [GID-TA10706] Expected publication date: 20 October 2021
-
Cabotegravir and rilpivirine for treating HIV-1 [ID3766]
Proposed [GID-TA10658] Expected publication date: 20 October 2021
-
Ozanimod for treating moderately to severely active ulcerative colitis [ID3841]
Proposed [GID-TA10732] Expected publication date: TBC
-
Selumetinib for treating inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 years and over [ID1590]
Proposed [GID-TA10535] Expected publication date: TBC
-
Ibalizumab for treating adults infected with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2720]
Proposed [GID-TA10657] Expected publication date: TBC
-
Lateral elbow resurfacing for arthritis
In development [GID-IPG10188] Expected publication date: TBC
-
Percutaneous insertion of a cystic duct stent for acute cholecystitis
In development [GID-IPG10189] Expected publication date: TBC
-
Liposuction for chronic lipoedema
In development [GID-IPG10190] Expected publication date: TBC
-
Endovascular forearm arteriovenous fistula creation for haemodialysis access
In development [GID-IPG10186] Expected publication date: TBC
-
Permanent His-bundle pacemaker implantation for heart failure
In development [GID-IPG10145] Expected publication date: 05 May 2021
-
High tibial osteotomy with adjustable magnetic nail insertion for symptomatic medial knee osteoarthritis
In development [GID-IPG10142] Expected publication date: TBC
-
Repetitive short- pulse transscleral cyclophotocoagulation for glaucoma
In development [GID-IPG10148] Expected publication date: TBC
-
Cervical ripening ballon for the induction of labour in women who have previously undergone cesarean section
In development [GID-IP1131] Expected publication date: TBC
-
Geniculate artery embolisation for pain from knee osteoarthritis
In development [GID-IPG10171] Expected publication date: TBC
-
Botulinum toxin injection into the urethral sphincter for idiopathic chronic non-obstructive urinary retention
In development [GID-IPG10172] Expected publication date: TBC
-
Endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by cholangiocarcinoma or pancreatic adenocarcinoma
In development [GID-IPG10067] Expected publication date: TBC
-
Implanting a baroreceptor stimulation device for resistant hypertension
In development [GID-IP1180] Expected publication date: TBC
-
Lung transplantation with ex-vivo perfusion
In development [GID-IP1046] Expected publication date: TBC
-
Microwave ablation for treating primary lung cancer and metastases in the lung
In development [GID-IPG10181] Expected publication date: TBC
-
Stereotactic radiosurgery for trigeminal neuralgia using the gamma knife
In development [GID-IPG10179] Expected publication date: TBC
-
Intramedullary distraction for lower limb lengthening
In development [GID-IPG10180] Expected publication date: TBC
-
Radiofrequency ablation for palliation of painful spinal metastases
In development [GID-IPG10158] Expected publication date: TBC
-
Magnetic resonance therapy for knee osteoarthritis
In development [GID-IPG10159] Expected publication date: TBC
-
Endobronchial vagal nerve ablation for chronic obstructive pulmonary disease
In development [GID-IPG10160] Expected publication date: TBC
-
Intramedullary distraction for upper limb lengthening
In development [GID-IPG10163] Expected publication date: TBC
-
Hysteroscopic morcellation of uterine leiomyomas (fibroids)
In development [GID-IPG10165] Expected publication date: TBC